SOLICITATION NOTICE
B -- Assessment of microRNA gene Expression Changes
- Notice Date
- 5/25/2012
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- 12-223-SOL-00124
- Archive Date
- 6/19/2012
- Point of Contact
- Howard Nesmith, Phone: 870-543-7459
- E-Mail Address
-
howard.nesmith@fda.hhs.gov
(howard.nesmith@fda.hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- Description/Specifications/Statement of Work Assessment of microRNA gene expression changes in four different cell types (2 lung, 1 endothelial, and 1 heart) using Next-Generation sequencing technology (Next-Gen). Next-Gen is required in order to provide full coverage of all the genes expressed in these cells after exposure to tobacco smoke condensates. The Next-Gen platform that is required is the Illumina sequencing technology. A total of 504 samples shall be analyzed so that the National Center for Toxicological Research can compare the effect of tobacco smoke condensates on the cellular expression of the genes. Ultimately, the gene expression changes will be used as biomarkers of exposure and harm to tobacco products. The following are the specific services required: a) Total RNA, including the microRNA fraction, will be provided by the Government. The Contractor must independently assess the quantity and quality of the RNA to ensure that it is acceptable for sequencing. b) Preparation of libraries from the microRNA that can be run on the Next-Gen platform. c) Sequencing of the libraries using Illumina sequencing technology using 50 bases minimum per read and a minimum of 3 - 5 million reads per sample. d) Alignment of the read data to the current reference human genome with transcript identifications assigned from miRBASE. e) The following data analysis and output shall be provided. a. FASTQ file for each sample. Files will be filtered to remove sequencing-specific adducts from the 3' end of each read. b. A table of the flow cell statistics outlining the quality and yield of the flow cell(s) where samples were clustered and sequenced. c. QC files regarding any presence of artifact/duplicate sequences, along with base distributions and qualities. d. Alignment of filtered reads to the human genome. e. An alignment file (BAM format) containing best alignments of each read to genome. f. De-multiplexing of Illumina barcodes, if applicable g. Provision of a tab-delimited file containing counts of each human miRBase (Sanger) accession for each sample. Samples will be shipped to the Contractor in 3 lots: 1 Lot of 168 samples will be shipped during the month of Sept 2012 1 Lot of 168 samples will be shipped during the month of Dec 2012 1 Lot of 168 samples will be shipped during the month of March 2013 The Vendor shall have 4 months from receipt of sample lots to run the samples and provide the analytical data. Data shall be sent at Vendor's expense to NCTR electronically and on a portable hard drive supplied by the Contractor. Within 30 days after the conclusion of analyses any samples not utilized or leftover shall be packed on dry ice and returned at the Contractor's expense to NCTR. All samples may be batched into one shipment.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/12-223-SOL-00124/listing.html)
- Place of Performance
- Address: U.S. Food and Drug Administration, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, Arkansas, 72079, United States
- Zip Code: 72079
- Zip Code: 72079
- Record
- SN02759340-W 20120527/120525235408-6e817919d258af94280256dae6c6f7ba (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |